PEPTIDES ENHANCING NEURONAL OUTGROWTH AND APPLICATION THEREOF

• US 20170362274A1
• Filed: 10/20/2015
• Published: 12/21/2017
• Est. Priority Date: 10/20/2014
• Status: Active Grant

• Current Assignee: Schweitzer Biotech Company Ltd.
• Original Assignee: Schweitzer Biotech Company Ltd.
• Inventors: YANG, Ying-Chen
• Granted Patent: US 10,407,465 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C12N 15/11 DNA or RNA fragments; Modified forms thereof DNA or RNA not used in recombinant technology, C07H21/00; Non-coding nucleic acids having a biological activity

Abstract

The present invention relates to peptides enhancing neuronal outgrowth, particularly to peptides that enhance neurite outgrowth and their application.

Claims

1. A peptide enhancing neuronal outgrowth, comprising the following sequence:

(R₁)_a-Asn-X₁-X₂-Pro-Gln-(R₂)_b 

 

(SEQ ID NO;

     3),

wherein

R₁ is an amino acid sequence comprising from 1 to 40 amino acids, wherein each amino acid is independently selected from the group consisting of naturally occurring amino acids and amino acid analogs;

R₂ is an amino acid sequence comprising from 1 to 40 amino acids, wherein each amino acid is independently selected from the group consisting of naturally occurring amino acids and amino acid analogs;

X₁ is an amino acid selected from the group consisting of nonpolar amino acids;

X₂ is an amino acid selected from the group consisting of naturally occurring amino acids and amino acid analogs; and

a and b are independently selected and are equal to zero and one.

2. The peptide of claim 1, wherein a and b are both zero.

3. The peptide of claim 1, wherein the sequence comprises at least one of NAIPQ (SEQ ID NO:

1), NPSPQ (SEQ ID NO;

     2), NFEPQ (SEQ ID NO;

     4), NMYPQ (SEQ ID NO;

     5), NIKPQ (SEQ ID NO;

     6), NLMPQ (SEQ ID NO;

     7), NVAPQ (SEQ ID NO;

     8), and NWLPQ (SEQ ID NO;

     9).

4. A polynucleotide encoding a peptide of claim 1.

5. A composition, comprising a peptide of claim 1 and a pharmaceutically acceptable vehicle.

6. A method for enhancing neuronal outgrowth, comprising contacting a neuronal cell with a peptide of claim 1 in an amount sufficient to enhance neuronal outgrowth.

7. The method of claim 6, wherein the neuronal cell is normal, damaged, or degenerated.

8. Use of a peptide of claim 1 in the manufacture of a medicament for ameliorating a symptom associated with neuronal damage or neurodegeneration in a subject.

9. The use of claim 8, wherein the symptom is selected from the group consisting of memory impairment, mental decline, coordination impairment, decline in survival rate, central nervous system lesions, Parkinson'"'"'s disease, Alzheimer'"'"'s disease, diseases affecting sensory neurons, limbic-cortical dysregulation, disorders associated with growth retardation and learning disabilities, Down'"'"'s disease, oxidative stress-induced neuronal death, aging-associated diseases, chronic diseases and conditions related to alcohol, disorders associated with drug abuse, pathological changes in wound tissues, and conditions caused by negative side effects of the therapeutic agent and treatment.

10. Use of a peptide of claim 1 in the manufacture of a composition for enhancing memory or learning abilities in a healthy subject.